Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
AR

AMEX · ARMP

Armata Pharmaceuticals, Inc.

Healthcare · Biotechnology

$4.18

Up+$0.08 (+1.95%)

Updated Sep 20, 2026, 12:44 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
391.74M
P/E ratio
-8.31
Dividend yield
0.00%
52-week range
$3.45 – $16.34
Volume
160.61K
Avg. volume
51.66K

Price performance

ARMP price history

1M range · 19 trading sessions · Daily adjusted prices

ARMP closed at $4.18 after 19 trading sessions, down 19.15% for the selected period.

Last close
$4.18
Period change
-19.15%
Period low
$4.07
Period high
$5.84
Daily close
View OHLC price history
ARMP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$4.07$4.40$4.00$4.18160.61K
Sep 17, 2026$4.32$4.32$4.09$4.10253.54K
Sep 16, 2026$4.40$4.44$3.985$4.07307.47K
Sep 15, 2026$5.24$5.35$4.23$4.40650.23K
Sep 14, 2026$6.17$6.6397$4.73$5.554.74M
Sep 11, 2026$5.30$5.5499$5.26$5.3843.63K
Sep 10, 2026$5.39$5.74$5.12$5.23115.38K
Sep 9, 2026$5.76$5.79$5.40$5.4117.89K
Sep 8, 2026$5.76$5.88$5.59$5.8247.38K
Sep 4, 2026$5.49$5.865$5.48$5.8448.03K
Sep 3, 2026$5.53$5.615$5.20$5.5249.5K
Sep 2, 2026$5.36$5.62$5.2708$5.5370.07K
Sep 1, 2026$5.51$5.68$5.19$5.2846.46K
Aug 31, 2026$5.35$5.52$5.18$5.5151.49K
Aug 28, 2026$5.37$5.445$4.985$5.3749.71K
Aug 27, 2026$5.42$5.47$4.73$5.43270.46K
Aug 26, 2026$5.59$5.59$5.30$5.4562.21K
Aug 25, 2026$5.23$5.70$5.23$5.5694.29K
Aug 24, 2026$5.10$5.26$4.862$5.1767.74K

Latest ARMP news

The latest Smart Investors Daily articles mentioning ARMP.

Stock researchCompany · Overview

ARMP research

Overview

Company profile and research snapshot.

Company profile

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
ARMP recent ratings
DateFirmRatingTarget
Feb 23, 2026HC Wainwright & Co.Buy—
Jan 5, 2026Jones TradingBuy—
May 19, 2025HC Wainwright & Co.Buy—
Dec 19, 2024HC Wainwright & Co.Buy—
Nov 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Therapy designation to AP-SA02, the Company's intravenously administered Staphylococcus aureu

Yahoo · Sep 10, 2026

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held in Ne

Yahoo · Sep 3, 2026

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology, a peer-reviewed journal.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By